SA
CRSP icon

Sanctuary Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Sanctuary Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Buy
11,315
+1,378
+14% +$72.6K ﹤0.01% 1816
2026
Q1 		$473K Sell
9,937
-1,239
-11% -$65.3K ﹤0.01% 1817
2025
Q4 		$586K Buy
11,176
+1,517
+16% +$90.9K ﹤0.01% 1631
2025
Q3 		$626K Buy
9,659
+567
+6% +$32.6K ﹤0.01% 1569
2025
Q2 		$442K Buy
9,092
+460
+5% +$17.8K ﹤0.01% 1697
2025
Q1 		$294K Buy
8,632
+453
+6% +$19.2K ﹤0.01% 1810
2024
Q4 		$344K Sell
8,179
-138
-2% -$6.52K ﹤0.01% 1909
2024
Q3 		$398K Buy
8,317
+1,258
+18% +$63.8K ﹤0.01% 1839
2024
Q2 		$381K Buy
+7,059
New +$408K ﹤0.01% 1818

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sanctuary Advisors's CRSP Position: Q2 2026 in Review

Sanctuary Advisors increased its CRISPR Therapeutics (CRSP) stake by 14% in Q2 2026, buying an estimated $72.6K and bringing the position to 11,315 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Sanctuary Advisors first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. The position peaked at $626K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Sanctuary Advisors held 11,315 shares of CRISPR Therapeutics worth $617K as of Q2 2026.
  • Sanctuary Advisors bought 1,378 CRISPR Therapeutics shares in Q2 2026, an estimated $72.6K.
  • CRISPR Therapeutics made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1816 holding.
  • Sanctuary Advisors first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Sanctuary Advisors's CRISPR Therapeutics position peaked at $626K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.